These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 3129505

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 4. Immunodeficiency in graft-versus-host disease (GVHD). II. Effects of GVHD-induced suppressor cells on CD4+ T cell clones.
    Wall DA, Hamberg S, Ferrara JL, Abbas AK.
    J Immunol; 1989 Jul 01; 143(1):74-8. PubMed ID: 2525150
    [Abstract] [Full Text] [Related]

  • 5. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec 01; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease.
    Holländer GA, Widmer B, Burakoff SJ.
    J Immunol; 1994 Feb 15; 152(4):1609-17. PubMed ID: 7907102
    [Abstract] [Full Text] [Related]

  • 8. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 9. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras.
    Brochu S, Baron C, Hétu F, Roy DC, Perreault C.
    J Immunol; 1995 Dec 01; 155(11):5104-14. PubMed ID: 7594519
    [Abstract] [Full Text] [Related]

  • 10. Natural suppressor (NS) activity from murine neonatal spleen is responsive to IFN-gamma.
    Maier T, Holda JH.
    J Immunol; 1987 Jun 15; 138(12):4075-84. PubMed ID: 2953798
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens.
    Krenger W, Snyder K, Smith S, Ferrara JL.
    Transplantation; 1994 Dec 15; 58(11):1251-7. PubMed ID: 7992370
    [Abstract] [Full Text] [Related]

  • 15. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T, Eto M, Lin T, Nishimura Y, Kong YY, Nomoto K, Nomoto K.
    J Immunol; 1994 Nov 01; 153(9):4311-20. PubMed ID: 7930630
    [Abstract] [Full Text] [Related]

  • 16. Significant MLR but not CTL responses against recipient antigens generated in T cells from bone marrow chimeras recovered from acute GVHD.
    Morohashi T, Ogasawara K, Kitaichi N, Iwabuchi K, Onoé K.
    Bone Marrow Transplant; 2000 Nov 01; 26(10):1069-76. PubMed ID: 11108305
    [Abstract] [Full Text] [Related]

  • 17. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 01; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 18. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 19. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 20. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component.
    Sykes M, Eisenthal A, Sachs DH.
    J Immunol; 1988 May 01; 140(9):2903-11. PubMed ID: 2966200
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.